Research programme: pain therapeutics - Akron MoleculesAlternative Names: AKR-210
Latest Information Update: 18 Oct 2013
At a glance
- Originator Akron Molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 16 Oct 2013 Preclinical trials in Pain in Austria (unspecified route) before October 2013